Back to Search

TACTI-003 (Two ACTive Immunotherapeutics): A Multicenter, Open Label, Randomized, Phase II Trial to Investigate a Soluble LAG-3 Fusion Protein, Eftilagimod Alpha (Efti; IMP321) in Combination With Pembrolizumab (PD-1 Antagonist) for First Line Treatment of Subjects With Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)

  • Protocol Number: 202108163
  • Principal Investigator: Adkins, Douglas
  • Cancer Types: Head & Neck

For more information on this trial, contact us here:


Brief Summary

Protocol Interventions